Emergent BioSolutions Inc.

Q2 2026 revenue was $234 million, up from $185 million at the prior guidance high end and above expectations; adjusted EBITDA was $97 million with a 41% margin, versus $33 million and 23% in the prior-year quarter. Adjusted gross margin was 58%, up from 49% a year ago; operating expenses were $54 million, down about $2 million year over year. Year to date, revenue was $390 million versus $363 million, adjusted EBITDA was $132 million versus $112 million, and adjusted gross margin was 56% versus 55% (up 100 basis points). Full-year 2026 guidance was lowered to revenue of $645 million-$675 million from $720 million-$760 million, adjusted EBITDA of $130 million-$150 million from $155 million-$175 million, adjusted gross margin of 42%-44%, adjusted net income of $10 million-$30 million, and GAAP net loss of negative $245 million to negative $225 million. Q3 revenue is expected to be $110 million-$130 million. Management said the cut was primarily due to lower commercial/NARCAN revenue, while MCM outlook remained generally intact.

Joe Papa said the company is focusing its multiyear transformation on operating discipline, balance-sheet strength, and growth areas aligned with Emergent’s mission in biodefense preparedness and naloxone. He emphasized that Q2 performance was strong, but also acknowledged a more competitive naloxone market with new entrants and more aggressive pricing. He framed the restructuring and portfolio changes as necessary to prepare the company for 2027 and beyond, while highlighting international MCM, product line extensions, and external business development as growth catalysts.

Richard Lindahl said the quarter beat internal and analyst expectations, with strong MCM execution and accelerated deliveries driving results. He highlighted $140 million of cash, $190 million of total liquidity, $590 million of gross debt, $450 million of net debt, and a 1.9x net leverage ratio; he also noted $145 million of receivables had been collected through July. He said the April 2026 refinancing created a new $150 million term loan with maturity extended to 2031 and lower interest expense, and that the board authorized a $75 million debt repurchase program aimed at senior unsecured notes. He quantified the restructuring as about $40 million of annualized net savings, partially offset by about $11 million of costs to achieve, and also cited a noncash $191 million impairment charge tied to NARCAN.

Analysts pressed on how Emergent plans to slow NARCAN erosion, and management pointed to brand strength, new product formats such as a carrying case and multipacks, and the company’s current market leadership, which Papa said remains above 50% share. On the strategic reset, Papa said R&D is still important, but combining internal R&D and external business development under one growth organization should improve speed and capital allocation. On MCM demand outside the U.S., management said international interest is building, citing roughly 20% of first-half MCM revenue coming from international sales and referencing global concerns about biothreats and AI-enabled risks. In Q&A, management also said the $145 million of receivables was normal working-capital collection, not securitization, and that the $75 million repurchase authorization is for senior unsecured notes.